| HORIZON | TRADES | WIN RATE | INSIDER RETURN | SPY RETURN | MEAN EXCESS | MEDIAN EXCESS | T-STAT |
|---|---|---|---|---|---|---|---|
| 7d | 8 | +75.00% | -3.96% | -0.34% | -3.62% | -7.90% | — |
| 14d | 8 | +75.00% | -5.11% | -0.38% | -4.73% | -10.31% | — |
| 30d | 8 | +75.00% | -8.71% | +0.93% | -9.64% | -18.07% | — |
| 60d | 8 | +62.50% | -3.45% | +2.30% | -5.75% | -11.01% | — |
| 90d | 8 | +87.50% | -12.06% | +2.36% | -14.88% | -24.33% | — |
| 180d | 8(1 pending) | +57.14% | +5.29% | +11.95% | -6.66% | -16.67% | — |
| 1y | 8(2 pending) | +83.33% | -25.49% | +21.62% | -47.11% | -52.40% | — |
| 2y | 8(4 pending) | +100.00% | -68.04% | +49.02% | -117.06% | -122.21% | — |
| COMPANY | TYPE | SHARES | PRICE | VALUE | HELD AFTER | TRADE DATE | FILED | DETAILS |
|---|---|---|---|---|---|---|---|---|
| NTLA INTELLIA THERAPEUTICS, INC. | SALE EVP, General Counsel | 1,211 | $13.78 | $16.7K | 156,794 | Mar 2, 2026 | Mar 3, 2026 ↗ | View → |
| NTLA INTELLIA THERAPEUTICS, INC. | PURCHASEGRANT Stock grant | 46,080 | — | — | 158,005 | Mar 1, 2026 | Mar 3, 2026 ↗ | View → |
| NTLA INTELLIA THERAPEUTICS, INC. | PURCHASEGRANT Stock grant | 65,829 | — | — | 65,829 | Mar 1, 2026 | Mar 3, 2026 ↗ | View → |
| NTLA INTELLIA THERAPEUTICS, INC. | SALE EVP, General Counsel | 10,397 | $9.21 | $95.8K | 101,528 | Jan 5, 2026 | Jan 7, 2026 ↗ | View → |
| NTLA INTELLIA THERAPEUTICS, INC. | SALE EVP, General Counsel | 2,572 | $8.99 | $23.1K | 111,925 | Mar 4, 2025 | Mar 4, 2025 ↗ | View → |
| NTLA INTELLIA THERAPEUTICS, INC. | PURCHASEGRANT Stock grant | 57,143 | — | — | 57,143 | Mar 1, 2025 | Mar 4, 2025 ↗ | View → |
| NTLA INTELLIA THERAPEUTICS, INC. | PURCHASEGRANT Stock grant | 40,000 | — | — | 114,497 | Mar 1, 2025 | Mar 4, 2025 ↗ | View → |
| NTLA INTELLIA THERAPEUTICS, INC. | SALE EVP, General Counsel | 7,074 | $12.18 | $86.2K | 74,497 | Jan 3, 2025 | Jan 7, 2025 ↗ | View → |
| NTLA INTELLIA THERAPEUTICS, INC. | SALE EVP, General Counsel | 2,297 | $32.99 | $75.8K | 81,571 | Mar 4, 2024 | Mar 5, 2024 ↗ | View → |
| NTLA INTELLIA THERAPEUTICS, INC. | PURCHASEGRANT Stock grant | 46,752 | — | — | 46,752 | Mar 1, 2024 | Mar 5, 2024 ↗ | View → |
| NTLA INTELLIA THERAPEUTICS, INC. | PURCHASEGRANT Stock grant | 32,394 | — | — | 83,868 | Mar 1, 2024 | Mar 5, 2024 ↗ | View → |
| NTLA INTELLIA THERAPEUTICS, INC. | SALE EVP, General Counsel | 3,805 | $29.46 | $112.1K | 51,474 | Jan 3, 2024 | Jan 5, 2024 ↗ | View → |
| NTLA INTELLIA THERAPEUTICS, INC. | SALE EVP, General Counsel | 1,088 | $43.88 | $47.7K | 55,279 | Mar 2, 2023 | Mar 3, 2023 ↗ | View → |
| NTLA INTELLIA THERAPEUTICS, INC. | PURCHASEGRANT Stock grant | 12,269 | — | — | 56,367 | Mar 1, 2023 | Mar 3, 2023 ↗ | View → |
| NTLA INTELLIA THERAPEUTICS, INC. | PURCHASEGRANT Stock grant | 24,539 | — | — | 44,098 | Mar 1, 2023 | Mar 3, 2023 ↗ | View → |
| NTLA INTELLIA THERAPEUTICS, INC. | PURCHASEGRANT Stock grant | 34,674 | — | — | 34,674 | Mar 1, 2023 | Mar 3, 2023 ↗ | View → |
| NTLA INTELLIA THERAPEUTICS, INC. | SALE EVP, General Counsel | 1,138 | $37.21 | $42.3K | 19,559 | Jan 4, 2023 | Jan 6, 2023 ↗ | View → |
| NTLA INTELLIA THERAPEUTICS, INC. | PURCHASEGRANT Stock grant | 9,648 | — | — | 20,697 | Mar 1, 2022 | Mar 3, 2022 ↗ | View → |
| NTLA INTELLIA THERAPEUTICS, INC. | PURCHASEGRANT Stock grant | 11,049 | — | — | 11,049 | Mar 1, 2022 | Mar 3, 2022 ↗ | View → |
| NTLA INTELLIA THERAPEUTICS, INC. | PURCHASEGRANT Stock grant | 9,648 | — | — | 9,648 | Mar 1, 2022 | Mar 3, 2022 ↗ | View → |
| NTLA INTELLIA THERAPEUTICS, INC. | PURCHASEGRANT Stock grant | 14,109 | — | — | 14,109 | Mar 1, 2022 | Mar 4, 2022 ↗ | View → |
| NTLA INTELLIA THERAPEUTICS, INC. | PURCHASEGRANT Stock grant | 130,000 | — | — | 130,000 | Jul 1, 2021 | Jul 6, 2021 ↗ | View → |
| KURA KURA ONCOLOGY, INC. | PURCHASEGRANT Stock grant | 125,000 | — | — | 125,000 | Jan 26, 2021 | Jan 28, 2021 ↗ | View → |
| KURA KURA ONCOLOGY, INC. | PURCHASEGRANT Stock grant | 25,000 | — | — | 25,000 | Mar 12, 2020 | Mar 17, 2020 ↗ | View → |